secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2026-09-14T20:07:12+00:00
Accession:  0001384101-26-000049
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte acquires Convergent Genomics for $150M cash plus $30M milestones
-------------------------------------------------------------------------

- Veracyte paid $150M upfront cash for Convergent, plus up to $30M milestone payments tied to UroAmp publications and reimbursement.
- Adds UroAmp urinary tumor DNA (utDNA) platform for bladder cancer, clinically validated in NMIBC for therapy monitoring and surveillance.
- Veracyte expects to commercialize initial UroAmp test in late 2028, subject to reimbursement timelines; plans additional indications.
- RUMBLE study: utDNA-positive patients post-BCG had 12-month recurrence-free survival 25% vs 91% for utDNA-negative patients.
- Veracyte maintains 2026 adjusted EBITDA guidance, including Convergent's ongoing operating expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000049/0001384101-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000049/vcyt-20260910.htm
  HTML page:      https://secwatch.observer/filing/0001384101-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer